. (1976). Annals of the Rheumatic Diseases, 35, 333-338. Indomethacin serum concentrations in man. Effects of dosage, food, and antacid. In the use of anti-inflammatory compounds, sustained serum levels are thought to be related to drug efficacy. This study shows that frequent clinical administration of indomethacin can result in sustained serum levels of the drug and that food and antacid may have important modifying effects on serum indomethacin concentrations. After oral ingestion by fasting subjects, indomethacin rapidly appeared in the serum, usually reaching peak concentrations in 30 to 90 minutes. Food delayed and decreased the mean peak level; antacid delayed the peak and slightly enhanced subsequent concentrations. With multiple dose schedules plateau levels were reached after 24 hours. When a total daily dose of 150 mg was given as 25 mg every 4 hours peak concentrations were the same but fluctuations were smaller and average concentrations were higher than with a dosage of 50 mg every 8 hours.
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Indomethacin (a 3-indolyl acetic acid derivative) is a widely used drug. Although its anti-inflammatory activity in animal models is exceptionally potent, its efficacy in rheumatoid arthritis has been controversial (Cooperating Clinics Committee of the American Rheumatism Association, 1967; O'Brien, 1967) . Reports on its metabolism (Duggan and others, 1972) , plasma concentrations (Caruso, 1971) , serum and synovial fluid pharmacokinetics (Emori and others, 1973) , and its interaction with salicylates (Lindquist and others, 1973; Van Arman, Nuss, and Risley, 1973) Multiple samples of venous blood were obtained after the initial dose to determine the response to a single dose given with food, and after the doses taken with breakfast on the second and fourth days to assess the cumulative effects of multiple doses. Drug administrations were then discontinued for 30 hours; when resumed, the randomization was reversed so that each subject would experience both dosage schedules (to permit comparison of the two schedules).
A third variation, also with a total daily dose of 150 mg indomethacin, was then evaluated by giving 25 mg every 4 hours during the waking hours and 50 mg at bedtime for 4 days. Bedtime doses were always given with 30 ml magnesium aluminium hydroxide gel (MgALOH gel). Blood specimens were collected 8 hours later to evaluate the effectiveness of these schedules in maintaining serum concentrations during sleep.
ASSAY METHOD
Specimens were centrifuged at the end of each trial day and the serum collected and frozen at -4°C until analysed within 2 months. Previous studies have shown no change in serum indomethacin concentrations during 4 months of storage at -4°C. Indomethacin assays were performed using a modification (J. E. Baer, personal comnmunication, 1970) of a spectrofluorometric method after Na 2CO3 extraction (Hucker and others, 1966) . In this method, 3 ml of sample are buffered with 2 ml 0 * 5 mol/l, pH 5 citrate;
the indomethacin is then extracted with 25 ml of a solution containing fluorescence-free heptane (97 Y.) and amyl alcohol (3 %). The heptane phase is washed twice with an equal volume of citrate buffer. A 15 ml aliquot of the washed heptane phase is alkalinized with 4 ml 0 2 mol/l Na2CO3 to extract the drug. The aqueous phase after centrifugation is removed for fluorescence intensity measurement. Occasionally further centrifugation is required because of turbidity in the aqueous phase at this point. The clear aqueous phase is read in an Aminco SPF spLlUpieUtropUoouUlrmter 4atUAMML1IJU waUV IHgUli I7J IllA and emission is measured at wave length 375 nm in quartz cuvettes. A water blank and two serum standards containing 2 -5 and 5 -0 ,tg/ml were analysed with each set of determinations. Repeated assays of standards, using fresh drugs at weekly intervals, were accurate to 0-08 ,g/ml (SEM 0 * 003). When 5 ,ug/ml of desmethyl indomethacin, an inactive metabolic product of indomethacin, was added to 2 * 5 ,tg/ml of indomethacin in serum, apparent indomethacin levels were 2-66 i 0 07 ,ug/ml on three trials. In earlier studies by our laboratory, no interference in the spectrofluorometric reading ofknown indomethacin concentrations occurred when 0 3 mg/ml of sodium salicylate was added to serum specimens (Champion and others, 1972 (Table  In 6 fasting males 50 mg indome a serum concentration curve simila normal healthy adults except for insignificant greater mean peak leve levels at 5 hours after drug ingeq parable to serum levels in normal v levels of 4 patients evaluated for 50 mg dose were almost identical the previous patients during the firs ever, after the initial rapid decline centrations, there was a gradual levels (Fig. 2) When a 25 mg dose was given to the 8 healthy ration was noted volunteers the mean peak level occurred at 30 k levels occurred minutes and was approximately half that of the drug ingestion. peak after the 50 mg dose to the same volunteers. 3 occasions were The T v for the interval between 60 and 240 minutes inutes after drug after the dose was 140 minutes (Fig. 1 ). In the ,receiving weekly patients 25 mg of the drug produced a mean peak h with one ex-serum level that was approximately twice that in were remarkably the normal volunteers. The difference between peak II). values for normals and patients was not statistically thacin produced significant because of marked individual varir to that seen in abilities in both groups. Serum levels 5 hours after r a slightly but drug ingestion were comparable in both groups 1 (Fig. 2) . Serum (Fig. 2) . stion were comThe 75 mg dose was studied only in the 8 normal olunteers. Serum volunteers. The mean peak serum level occurred 9 hours after a after 60 minutes and was twice that after the 50 mg to those seen in dose. The decline after peak concentrations was st 5 hours. How-more rapid (T v between 60 and 240 minutes was from peak con-37 minutes), and 5 hours after drug ingestion the decline in serum mean serum concentration was approximately equal to that seen after both smaller doses (Fig. 1) . A 100 mg dose given to 4 normal volunteers (described above) showed a somewhat delayed peak (2 hours after drug) that was three times the peak after the 50 mg dose to the 8 healthy volunteers (Fig. 1) . The T I after the occurrence of the mean peak level was 30 minutes as measured between 60 and 240 minutes after the dose. One subject was followed for 71 hours, the other 3 for 1 3/4 to 3 hours.
The addition of 30 ml MgALOH gel to a 50 mg dose delayed the occurrence of the mean peak con->---centration and slightly increased subsequent concentrations without decreasing the rate of decline o of serum concentrations (Fig. 3) .
In 6 hospitalized patients administration of 25 mg and 50 mg indomethacin (both 25 mg and 50 mg) with a ormals and to mo standard hospital breakfast resulted in a delayed and nts with rheumatic decreased mean peak serum level when compared with the same doses given to fasting subjects. Serum levels 6 hours after the 25 mg dose and 8 hours after the 50 mg dose were similar to those at comparable times after fasting administration (Fig. 3) . (FIG. 4) After the fourth dose (day 2) 50 mg indomethacin given every 8 hours with a meal or snack produced a concentration curve with a mean peak level of I 48 ± 0 31 Fg/ml occurring 90 minutes after drug administration. A clear-cut biphasic removal pattern was not apparent as after the fasting doses of indomethacin alone, perhaps because fewer timepoints were assayed. 8 hours after drug ingestion serum levels were roughly 30 % greater than serum levels after a single 50 mg fasting dose. The serum concentration curve after the 10th dose (on day 4) of continuous therapy was almost identical to that described above after the fourth dose. When 25 mg of the drug was given every 4 hours with a meal or substantial snack, peak serum levels were very similar to peak levels after the repeated 50 mg doses (as measured on day 2). However, mean serum levels 31 hours later were twice that of the minimum serum levels observed before the next 50 mg dose on the every 8-hour schedule. On day 4 the serum concentration curve for a dose of 25 mg every 4 hours also remained unchanged.
SIDE EFFECTS
Patients complained less than normal volunteers of unfavourable side effects, the major complaint of the normal volunteers (9 of 12) being an ill-defined feeling of 'muzziness'. None complained of gastrointestinal symptoms. The patients, although specifically asked, did not complain of drowsiness. 3 of 10 patients did complain of slight epigastric discomfort, noted after a week of therapy on the multiple dose schedule.
Discussion
This study is based on the assumption that side effects and toxicity are more closely related to serum drug levels than to dosage in drugs with rapidly reversible effects. Although this assumption has been proved true for only a small number of drugs, it is generally accepted. In addition, the importance of sustained serum and tissue levels of a drug for maximum effectiveness has also been emphasized (Koch-Weser, 1972; Hvidberg, Lausen, and Jansen, 1972 In clinical practice indomethacin is often given in divided doses at 8-or 12-hour intervals. Because of the frequent association of anti-inflammatory drugs with symptoms of gastric irritation, it is usually given postprandially or with antacids. This study shows that frequency of administration, dosage, food, and antacids have important modifying effects on serum indomethacin concentrations. group.bmj.com on July 7, 2017 -Published by http://ard.bmj.com/ Downloaded from Indomethacin rapidly appears in the serum after oral administration of the drug. Peak serum levels occur in 30-90 minutes, and increase with increasing single doses of the drug. After the peak there is a rapid decline of serum concentrations during the next 3 hours followed by a much slower rate of decrease in serum concentrations (between 5 and 9 hours after the dose). In a previous study (Emori and others, 1973) we found that indomethacin concentrations in synovial fluid approximate those in the serum during this later phase (between 5 and 9 hours after the dose). The kinetics in the first 3 hours after the dose are complex, and are influenced by drug absorption, distribution, and excretion. However, during the subsequent slower disappearance of indomethacin from the serum (and synovial fluid), it appears that the drug is re-entering the serum from tissue stores, is being metabolized, and excreted. These findings support Duggan's suggestion of an initial distributive phase from the vascular to the extravascular compartment and a subsequent phase of metabolism and re-entry of the drug from tissue stores (Duggan and others, 1972) . Food delayed and decreased the mean peak level. Antacid delayed the peak and slightly enhanced subsequent concentrations. Antacids have been shown to have no effect upon (Lansdown and Radzin, 1963) nor depress or enhance (Hurwitz, 1971 ) the absorption and subsequent blood levels of orally ingested drugs. These effects have been explained by 'physiochemical' changes in the drug, or by physiological changes in the subject, caused by antacid ingestion (Rosenoer and Gill, 1972) .
Both multiple dose schedules (150 mg daily in 3 or 6 divided doses) showed a cumulative effect by day 2, but without further increase in serum levels when remeasured on day 4. The smaller, more frequent 25 mg doses resulted in peak concentrations equal to those after the larger, less frequent 50 mg doses, but with much smaller fluctuations in serum concentrations. This smaller amplitude of fluctuations resulted in a greater mean serum concentration with the more frequent 25 mg doses. The effects of some important factors of clinical administration of indomethacin have been measured, but the great individual variability in serum drug levels and of other factors not measured preclude accurate prediction of drug levels after a given dose(s) to an individual. For accurate dosage adjustment in individual patients it will be necessary to measure drug concentrations during therapy rather than attempt to extrapolate these data. However, if the anti-inflammatory efficacy and toxicity of indomethacin are related to sustained tissue concentrations of the drug rather than to brief peak serum levels, relatively stable indomethacin levels can be maintained during chronic therapy by the use of frequent small doses of the drug. Fluctuations in serum levels can be further decreased by administration with meals or antacid.
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